Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 2, 2009, Pages 190-195

  Inotai, András ^a   Mészáros, Ágnes ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cost effectiveness; COX2 inhibitors; Decision tree; Rheumatoid arthritis

Indexed keywords

ACTIVE AGENTS; ADVERSE EVENTS; CELECOXIB; COX2 INHIBITORS; CYCLOOXYGENASE 2; DECISION TREE MODELS; ECONOMIC EVALUATIONS; INCREMENTAL COST; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; PROTON PUMP INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RHEUMATOID ARTHRITIS; RISK PROFILE; SIDE EFFECT; THERAPEUTIC STRATEGY; THIRD PARTIES; TORNADO DIAGRAMS;

COST EFFECTIVENESS; COSTS; DECISION TREES; DRUG INTERACTIONS; HEALTH; HEALTH RISKS; RISK PERCEPTION; SENSITIVITY ANALYSIS;

DRUG PRODUCTS;

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; MEDICAL DECISION MAKING; PEPTIC ULCER; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SIMULATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION TREE; DRUG COMBINATION; ECONOMICS; HEALTH CARE COST;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DECISION TREES; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; PROTON PUMP INHIBITORS; QUALITY-ADJUSTED LIFE YEARS;

EID: 67549119986     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090242     Document Type: Article

References (21)

1. Cantor SB. Pharmacoeconomics of coxib therapy. J Pain Symptom Manage. 2002;24(Suppl):S28-S37.
2. Coruzzi G, Venturi N, Spaggiari S. Gastrointestinal safety of novel non-steroidal anti-inflammatory drugs: Selective COX-2 inhibitors and beyond. Acta Biomed. 2007;78:96-110. (Pubitemid 350125132)
3. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: Nonselective diffusion of a selectively cost-effective innovation [see comment]. Arch Intern Med. 2005;165:171-177.
4. Drummond MF, Schulper MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
5. El-Serag HB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: The use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002;162:2105-2110. (Pubitemid 35168219)
6. Fleischmann R, Tannenbaum H, Patel NP, et al. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis. BMC Musculoskelet Disord. 2008;9:32. (Pubitemid 351551366)
7. Hungarian DRG system [HBCs 5.0]. http://www.eski.hu/ new3/adatok/kodok/ HBCs-5.0-torzs.htm. Accessed August 5, 2008.
8. Hungarian drug formulary Pharmindex. http://www. pharmindex.hu/gyogyszer- kereso.xhtml. Accessed August 5, 2008.
9. Indicators of the treatment of AMI. 30 days rough mortality. (AMI kórházi ellátásának indikátorai. 30 napos nyers halálozás. 2006. November). http://www.oep.hu/portal/ page? -pageid=6,33139&-dad=portal&-schema=PORTAL. Accessed February 2, 2008.
10. Indicators of the treatment of AMI. Ratios of different cardiologic interventions in the treatment of AMI. (AMI kórházi ellátásának indikátorai. Kardiológiai beavatkozásban részesültek aránya az AMI esetek körében. 2006. November). http://www.oep.hu/portal/page?-pageid=6, 33139&-dad=portal&- schema=PORTAL. Accessed February 2, 2008.
11. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage. 2003;25(Suppl):S32-S40.
12. Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol. 2007;7:25. (Pubitemid 47162168)
13. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of non-steroidal anti-inflammatory drugs [see comment]. Arthritis Rheum. 1998;41:16-25. (Pubitemid 28041918)
14. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patientswith osteoarthritis or rheumatoid arthritis. Arthritis Rheum. 2003;49:283-292. (Pubitemid 36682393)
15. NICE. Cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs - etodolac, meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib - for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation. http://www.nice.org.uk/guidance/index.jsp?action= download&o=34820. Accessed August 5, 2008.
16. Péntek M, Szekanecz Z, Czirják L, et al. Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary [Abetegség progresszióhatasa az egészségi állapotra, életmincombining double acute accentoségre és költségekre rheumatoid arthritisben Magyarországon] . Orvosi Hetilap. 2008;149:733-741.
17. Protocol of the Ministry of Health, Hungary - Pharmacological treatment of pain and inflammation in rheumatic diseases. (Az Egészségü gyi Minisztérium szakmai protokollja - Gyógyszeres fájdalomcsíllapátás és gyulladá sgátlás a reumatológiai betegségekben) http://www.eum.hu/ egeszsegpolitika/minosegfejlesztes/reumatologia. Accessed August 5, 2008.
18. Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133:790-798.
19. Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA. 2000;284:1247-1255. (Pubitemid 30691365)
20. Spiegel BMR, Chiou CF, Ofman JJ. Minimizing complications from non-steroidal anti-inflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups.[see comment]. Arthritis Rheum. 2005;53:185-197.
21. Yun HR, Bae SC. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol Int. 2005;25:9-14.